CANC
Tema Oncology ETF·Financial Services
37.27
1.598%(−0.61)
Market ClosedLast Updated: — ET
52W L: $22.4852W H: $38.34
CANC NEWS
seekingalpha.com
1d ago
CANC: I Give A Hold Rating To This ETF That Invests In Cancer-Fighting Stocks
Tema Oncology ETF receives a Hold rating due to inconsistent returns but it does currently have a high Quant Ranking in the healthcare subclass. CANC offers diversified exposure across market caps and geographies, focusing on firms combating cancer through biotech, pharmaceuticals, diagnostics, and devices. The ETF holds 55 stocks, with top 10 comprising 40% of the portfolio, balancing established giants and innovative small-caps.
businesswire.com
Feb 18
Tema Appoints ETF Industry Leader Steve Munroe as President
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this role, Mr. Munroe will partner with Tema Founder and CEO Maurits Pot and the firm's leadership team to accelerate the company's next phase of growth. He will oversee branding, marketing, distribution, and product strategy as Tema continues to gain momentum—raising more than $1 billion in net new assets o.
defenseworld.net
Feb 8
Thrivent Financial for Lutherans Decreases Stake in Tema Oncology ETF $CANC
Thrivent Financial for Lutherans cut its holdings in shares of Tema Oncology ETF (NASDAQ: CANC) by 84.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 147,472 shares of the company's stock after selling 810,003 shares during the period. Thrivent Financial
